Member Info for Polio

Crazy how much stock is getting bought

It is massive news, the only reason it hasn't taken off yet is because we are a few months away. However, when it does happen we will not be sat around this share price!

Keep building folks

Realistically what should the MCAP be?

GL all

1000% today?

Lol comek2

so true

All in good time

Lol Steve

I have a feeling it could be more than that

Anyway, another step in the right direction isn't it!

A CE mark will be the next big thing and then we are all in

Renalytix is pursuing a CE mark in response to growing international strategic partner interest, having already entered in discussions with a Top 10 global pharmaceutical company on the use of the test for targeted enrollment of patients in a global clinical trial and potential use as a companion diagnostic for a novel therapy.

CE Mark application submission

In response to strategic partner interest in use of kidneyintelX.dkd in a clinical trial in Europe

LONDON and NEW YORK, 1 October 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that it has submitted an application for CE Mark certification in accordance with the European Union In-Vitro Diagnostics Regulation (IVDR) to enable clinical use and reporting of the kidneyintelX.dkd™ test across the EU.

The kidneyintelX.dkd prognostic blood test is commercially available in the US and indicated for use as an aid in predicting level of risk (high, moderate, low) for progressive decline in kidney function in type 2 diabetes patients with diagnosed chronic kidney disease stages 1-3b.

Renalytix is pursuing a CE mark in response to growing international strategic partner interest, having already entered in discussions with a Top 10 global pharmaceutical company on the use of the test for targeted enrollment of patients in a global clinical trial and potential use as a companion diagnostic for a novel therapy. When combined with FDA approval, the CE Mark will further embed kidneyintelX.dkd as the global precision medicine standard in Chronic Kidney Disease (CKD).

On successful achievement of a CE mark, expected in H1 2026, Renalytix anticipates further commercial opportunities, including international distribution partnerships, in FY26 and/or FY27.

According to independently published estimates, CKD is a significant global health issue affecting nearly 850 million people globally with close to 100 million of those being European individuals.

A diagnostic blood test requires CE mark certification which is subject to a rigorous assessment of data on safety, analytical validation, software controls and clinical performance in compliance with IVDR.

2 x 500k buys got us back up. Just showing

9.50 sell

9.70 to buy

And just like that we are back

No point predicting lads. Keep building your shares up as you never know when we will release more news

MMs will go fishing for easy shares of PI's it happens alllll the time.

9.5p is the base here, if you can buy below then do so

Yep totally with you, been in on this for a few months and holding!! Massive from here on speculation alone

What’s going on here then!!!! Holy moly she going to the moon

MMs ready to let this one go aren’t they

Ranger

The company’s statements suggest they initiated some mining activity (especially artisanal, small scale) from December 2024 onward, which would carry over into Jan and Feb.

• The news of a “temporary pause” implies there was ongoing operations in Feb that could be paused.

• But their financials (nil revenue, nil cost of sales) strongly indicate no meaningful commercial production or sales in Jan/Feb (or over the six months), at least nothing material.

They likely did some limited mining / development / artisanal operations, but not significant, fully commercial production. If so, it was either pre-commercial, internal, or small scale, and not at a level that could produce meaningful revenue.

It is clear. We have no revenue streams as of yet and are working at a loss as we are in a pre production stage. We’ve known this for a very long time!